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Introduction
High hyperdiploid (HeH) cases (51-67 chromosomes), char-
acterized by non-random multiple chromosomal gains, form
one of the largest subgroups of pediatric B-cell precursor acute
lymphoblastic leukemia (ALL).1 HeH cases are generally asso-
ciated with favorable clinical features, such as a low white
blood cell (WBC) count, lack of extramedullary manifesta-
tions, and age between 2-5 years, and have a superior out-
come, with overall survival (OS) rates exceeding 90% in most
contemporary treatment protocols.1-7 This notwithstanding, a
substantial proportion of patients relapses, so event-free sur-
vival (EFS) rates are only 70-80%.4-7 Several attempts have
been made to define the clinical and genetic characteristics
present at the time of diagnosis that would enable identifica-
tion of patients who will respond poorly to standard-risk
treatment and who could, therefore, benefit from more inten-
sive therapy. However, only a few clinical features have been
shown to be associated with decreased EFS within the HeH
group, namely age >10 years, male gender, and bone marrow
fibrosis.5,8,9 As regards genetic factors, it has been suggested
that some karyotypic patterns and aberrations – low modal
chromosome number, lack of certain trisomies, and the pres-
ence of various structural changes – confer a more dismal out-
come, albeit with conflicting results in different studies.2,4,5,7,9-13
The prognostic impact of the “triple trisomies”, i.e., concur-
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Between 1992 and 2008, 713 high hyperdiploid acute lymphoblastic leukemias in children aged 1-15 years were
diagnosed and treated according to the Nordic Society for Pediatric Hematology and Oncology acute lymphoblastic
leukemia 1992/2000 protocols. Twenty (2.8%) harbored t(1;19), t(9;22), der(11q23), or t(12;21). The median age of
patients with “classic” high hyperdiploidy was lower than that of patients with translocation-positive high hyper-
diploidy (P<0.001). Cases with triple trisomies (+4, +10, +17), comprising 50%, had higher modal numbers than the
triple trisomy-negative cases (P<0.0001). The probabilities of event-free survival and overall survival were lower for
those with white blood cell counts ≥50x109/L (P=0.017/P=0.009), ≥5% bone marrow blasts at day 29
(P=0.001/0.002), and for high-risk patients (P<0.001/P=0.003), whereas event-free, but not overall, survival, was
higher for cases with gains of chromosomes 4 (P<0.0001), 6 (P<0.003), 17 (P=0.010), 18 (P=0.049), and 22 (P=0.040),
triple trisomies (P=0.002), and modal numbers >53/55 (P=0.020/0.024). In multivariate analyses, modal number and
triple trisomies were significantly associated with superior event-free survival in separate analyses with age and
white blood cell counts. When including both modal numbers and triple trisomies, only low white blood cell counts
were significantly associated with superior event-free survival (P=0.009). We conclude that high modal chromo-
some numbers and triple trisomies are highly correlated prognostic factors and that these two parameters identify
the same subgroup of patients characterized by a particularly favorable outcome. 
High modal number and triple trisomies are highly correlated favorable
factors in childhood B-cell precursor high hyperdiploid acute 
lymphoblastic leukemia treated according to the 
NOPHO ALL 1992/2000 protocols
Kajsa Paulsson,1 Erik Forestier,2 Mette K. Andersen,3 Kirsi Autio,4 Gisela Barbany,5 Georg Borgström,4 Lucia Cavelier,6
Irina Golovleva,7 Sverre Heim,8 Kristiina Heinonen,9 Randi Hovland,10 Johann H. Johannsson,11 Eigil Kjeldsen,12 Ann
Nordgren,5 Lars Palmqvist,13 and Bertil Johansson,1,14 on behalf of the Nordic Society of Pediatric Hematology and
Oncology (NOPHO), the Swedish Cytogenetic Leukemia Study Group (SCLSG), and the NOPHO Leukemia Cytogenetic
Study Group (NLCSG)
1Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2Department of Medical
Biosciences, University of Umeå, Umeå, Sweden; 3The Cytogenetic Laboratory, The University Hospital Rigshospitalet, Copenhagen,
Denmark; 4Helsinki and Uusimaa Hospital Group, HUSLAB Laboratory of Genetics, Helsinki, Finland; 5Department of Molecular
Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; 6Department of Genetics and Pathology, Uppsala University,
Uppsala, Sweden; 7Department of Medical Biosciences, Medical and Clinical Genetics, University of Umeå, Umeå, Sweden;
8Department of Medical Genetics, The Norwegian Radium Hospital, Oslo University Hospital, and Centre for Cancer Biomedicine,
Faculty of Medicine, University of Oslo, Oslo, Norway; 9Genetic Laboratory, ISLAB, Kuopio, Finland; 10Center of Medical Genetics and
Molecular Medicine, Haukeland University Hospital, Helse-Bergen HF, Norway; 11Department of Clinical Genetics and Cytogenetics,
University Hospital, Reykjavik, Iceland; 12Cancer Cytogenetic Laboratory, Department of Hematology, Aarhus University Hospital,
Aarhus, Denmark; 13Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Göteborg,
Sweden; and 14Department of Clinical Genetics, University and Regional Laboratories Region Skåne, Lund, Sweden
ABSTRACT
rent +4, +10, and +17, is debated; they have been reported
to be associated with low risk by the Children’s Oncology
Group (COG) but not in UK trials.7,13 Furthermore, +18 has
been correlated with a lower risk of relapse, at least in the
UK.5,7 In order to address the important issue of clinical
and genetic risk factors in HeH, we ascertained and
reviewed all such cases diagnosed between 1992 and 2008
in Nordic countries and treated according to the Nordic
Society for Pediatric Hematology and Oncology (NOPHO)
ALL 1992 and ALL 2000 protocols,14 a cohort of more than
700 patients. 
Methods
Patients and cytogenetics
The following inclusion criteria were applied: B-cell precursor
ALL diagnosed in children aged 1-15 years in the Nordic countries
(Denmark, Finland, Iceland, Norway, and Sweden) between 1992
and 2008 that were high hyperdiploid (51-67 chromosomes) or, in
cases in which cytogenetic analysis failed or those with a “normal”
karyotype, showing a gain of more than four extra chromosomes
by interphase fluorescence in situ hybridization (FISH) or having a
DNA index greater than 1.12.1,15,16 Chromosome banding analyses
were performed on bone marrow/peripheral blood samples using
standard methods by 15 different cytogenetic laboratories in the
Nordic countries. All abnormal karyotypes have been centrally
reviewed annually since 1996 in  Sweden and since 2000 in all five
Nordic countries. Cases with t(1;19)(q23;p13)/TCF3-PBX1,
t(9;22)(q34;q11)/BCR-ABL1, der(11q23)/MLL rearrangement, or
t(12;21)(p13;q22)/ETV6-RUNX1 in a high hyperdiploid back-
ground (translocation-positive high hyperdiploidy; t-HeH) were
not excluded from the initial analyses, nor were cases with incom-
plete karyotypes. Since 2000, the NOPHO protocols14 have
required, apart from conventional G-banding, targeted analyses
for t(1;19), t(9;22), der(11q23), and t(12;21) by FISH, Southern blot,
or reverse transcriptase-polymerase chain reaction (PCR).
Although such investigations were not compulsory in the ALL
1992 protocol,14 several of the participating laboratories had per-
formed prospective analyses of the above-mentioned rearrange-
ments since the mid 1990s, in some instances also retrospectively. 
The study was approved by the Regional Ethical Review Board
at Lund University and informed consent was obtained according
to the Declaration of Helsinki.
Statistical analyses
The PASW Statistics 18.0.0 software for Windows (SPSS Inc.,
Chicago, IL, USA) was used for all calculations. The significance
limit for two-sided P values was set at less than 0.05. Modal chro-
mosome numbers were defined as the highest number in kary-
otypes with a range of chromosome numbers. In the analysis of
the prognostic impact of +4, +10, +17 (triple trisomies), and +18,
cases were considered completely informative if no marker chro-
mosomes were present; if markers were found, cases could not be
classified as negative for these specific trisomies. Possible differ-
ences between subgroups were investigated using two-sided
Mann-Whitney’s tests, two-tailed Fisher’s exact probability tests,
and c2 tests. The probabilities of EFS (pEFS) and OS (pOS) at 5 and
10 years were calculated using the Kaplan-Meier method, and sub-
groups were compared using the log rank test. The following
parameters were investigated: t-HeH, modal number, triple tri-
somies, all individual gains, structural changes as such, 1q gain, 6q
deletion, 17q gain, gender, age, WBC count, mediastinal mass,
central nervous system involvement, bone marrow remission at
days 15 and 29, treatment protocol, and risk group (standard risk,
intermediate risk, high risk).14 Multivariate analysis using a Cox
regression model was performed to identify factors that had an
independent impact on pEFS and pOS. In the analysis of pEFS,
events consisted of induction failure, resistant disease, relapse,
death in first complete remission, and second malignant neo-
plasms. In the analysis of pOS, death from any cause was the end-
point. The median observation time for patients in continuous first
complete remission was 126 months (range, 24-235 months). The
NOPHO leukemia registry is updated annually; follow-up data
were extracted in April, 2012.
Results
Basic cytogenetic features
A total of 713 cases were ascertained and reviewed,
accounting for 30% of all Nordic B-cell precursor ALL in
children aged 1-15 years diagnosed between 1992 and
2008. Of these, 695 (97%) displayed G-banded karyotypes
with 51-67 chromosomes, ten (1.4%) were identified by
interphase FISH, and eight (1.1%) by DNA flow analyses.
Twenty (2.8%) cases harbored one of the ALL-associated
translocations t(1;19) (n = 4), t(9;22) (n = 6), der(11q23) (n
= 3), or t(12;21) (n = 7) and were classified as t-HeH. The
remaining 693 were “classic” HeH B-cell precursor ALL.
Cytogenetic features of the 693 high
hyperdiploid cases
Of the 693 cases, modal chromosome numbers were
known in 675; the median mode was 55 chromosomes
(Online Supplementary Figure S1A). Triple trisomies
(+4,+10,+17) were present in 175 (50%) and absent in 178
(50%) of 353 informative cases. The triple trisomy-posi-
tive cases had a median mode of 56 chromosomes (range,
51-65), whereas the negative cases had a median mode of
55 chromosomes (range, 51-62) (Online Supplementary
Figure S1B and C) (P<0.0001). 
A total of 298 cases were informative for all chromo-
somes as regards numerical changes. The most frequently
gained chromosomes were 21 (98.4%), X (90.0%), 6
(83.2%), 14 (82.8%), 18 (77.7%), 4 (77.3%), 17 (73.1%), 10
(71.2%), and 8 (37.5%) (Online Supplementary Figure S2).
All other chromosomes were gained in less than 25% of
cases. 
Among 456 informative cases, 237 (52%) had structural
chromosome changes, with the most common being 1q
gain (68/337; 20%), 6q deletion (14/318; 4.4%), and 17q
gain (11/311; 3.5%). 
Cytogenetic features of the 20 translocation-positive
high hyperdiploid cases
The karyotypes of the t-HeH cases are listed in Online
Supplementary Table S1. The median modal chromosome
numbers were 57 for the t(1;19) group, 56-57 for t(9;22), 54
for der(11q23), and 52 for t(12;21). Among the nine
informative cases, the most frequent gains were +X
(89%), +21 (89%), +6 (67%), +10 (67%), +4 (56%), +14
(56%), and +18 (44%). All other chromosomes were
gained in less than 25% of cases.
Clinical features at diagnosis
The male/female sex ratio was close to 1.0 in all cytoge-
netic subgroups, with the possible exception of t(1;19)-
positive cases (Table 1). Two patients had Down syn-
drome (DS), neither of whom had t-HeH. The median age
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was lower (P<0.001) among the HeH cases (3.78 years;
range, 0.95-15.0) than the t-HeH cases (5.92 years; range,
2.86-14.19), whereas no significant differences were seen
between these groups regarding WBC counts or incidence
of extramedullary leukemia. 
Clinical features at diagnosis in relation to karyotypic
patterns of the high hyperdiploid cases
Among the 688 HeH cases treated according to the
NOPHO ALL 1992/2000 protocols,14 670 were informative
for modal chromosome numbers. Clinical features and
survival in relation to modal number are given in Online
Supplementary Table S2. There were no significant differ-
ences in age or WBC count distributions between cases
with 51-53 chromosomes versus cases with more than 53
chromosomes or between cases with 51-55 chromosomes
versus cases with more than 55 chromosomes. The modal
chromosome number distributions did not differ between
boys and girls. 
As regards cases positive and negative for triple tri-
somies, there was no impact of age, WBC count, or gen-
der. Among the most frequent gains, there were signifi-
cant differences in age distributions for chromosomes 6
(median age 4.74 years for disomy versus 3.42 for trisomy;
P<0.001), 17 (median 4.65 for disomy versus 3.43 for tri-
somy; P=0.001), and 18 (median age 4.51 years for disomy
versus 3.44 for trisomy; P=0.021) and in WBC counts for
chromosome 4 (median WBC count 10.8 for disomy versus
6.1 for trisomy; P=0.036). Gains of chromosomes 4 and 6
were more common in females than in males (85% versus
71%; P=0.002 and 89% versus 80%; P=0.021). The pres-
ence of structural changes as such, 1q gain, 6q deletion, or
17q gain did not vary in relation to WBC counts or gender,
whereas the age distribution differed significantly
between cases with and without structural changes (medi-
an age 4.10 versus 3.76; P=0.028).
Risk classification and treatment response
Data on risk stratification and treatment response,
including frequency and types of primary events, in the
688 HeH and the 20 t-HeH patients treated according to
the NOPHO ALL 1992/2000 protocols, are summarized in
Table 2. Since there were no significant differences in pEFS
at 5 and 10 years between patients treated according to
the ALL 1992 or 2000 protocols [ALL 1992: 0.82, standard
error (SE) 0.02 and 0.79 SE 0.02, respectively, versus ALL
2000: 0.82 SE 0.02 and 0.81 SE 0.02, respectively; P=0.683]
or in pOS at 5 and 10 years (ALL 1992: 0.90 SE 0.02 and
0.88 SE 0.02, respectively, versus ALL 2000: 0.92 SE 0.02
and 0.91 SE 0.02, respectively; P=0.297), data from these
two treatment regimens were combined in the subsequent
analyses. 
Forty-nine percent of the HeH cases were classified as
standard risk, 38% as intermediate risk, and 14% as high
risk (Table 2). The corresponding frequencies for t-HeH
were 40%, 5%, and 55%; however, it should be stressed
that the presence of t(1;19), t(9;22), and der(11q23) was
risk-stratifying in the protocols. The majority of patients,
irrespectively of whether they had HeH or t-HeH, were in
morphological remission at day 15 and close to 100% had
less than 5% bone marrow blasts at day 29 (Table 2).
There were no significant differences between the HeH
and t-HeH groups as regards achievement of complete
remission or in proportions of patients in first complete
remission, induction failure/resistant disease, relapse,
death in first complete remission, or development of a sec-
ond malignant neoplasm.
Survival in relation to clinical features among the 708
patients treated according to the NOPHO ALL 1992/
2000 protocols
For the entire patient cohort, the 5- and 10-year pEFS
were 0.82 and 0.80, respectively; the corresponding pOS
were 0.91 and 0.89 (Online Supplementary Table S3; Online
Supplementary Figure S3). There were no significant differ-
ences in pEFS (P=0.439) or pOS (P=0.393) between the 688
HeH and 20 t-HeH patients. 
The impact of gender, age, WBC count, central nervous
system disease, mediastinal mass, risk group, and percent-
age of bone marrow blasts at days 15 and 29 on pEFS and
pOS was investigated in the 688 HeH patients. Survival
rates were significantly lower for boys (pEFS only;
P=0.006; Figure 1), for patients with WBC counts
≥50x109/L (pEFS; P=0.017 and pOS; P=0.009; Figure 2) or
≥5% bone marrow blasts at days 15 (pEFS; P<0.001 and
pOS; P<0.001) and 29 (pEFS; P=0.001 and pOS; P=0.002),
and for patients grouped as high risk (pEFS; P<0.001 and
pOS; P=0.003) (Table 3).
Survival in relation to cytogenetic features among 
the 688 high hyperdiploid patients treated according
to the NOPHO ALL 1992/2000 protocols 
The presence of trisomies/tetrasomies 4, 6, 17, 18, and
22 was significantly associated with a higher pEFS; none
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Table 1. Clinical features at the time of diagnosis of 713 children with high hyperdiploid B-cell precursor ALL.
Total HeH t(1;19)1 t(9;22)1 der(11q23)1 t(12;21)1
(n = 713; 100%) (n = 693; 97.2%) (n = 4; 0.6%) (n = 6; 0.8%) (n = 3; 0.4%) (n = 7; 1.0%)
Male/female (ratio) 359/354 (1.0) 347/346 (1.0) 3/1 (3.0) 3/3 (1.0) 2/1 (2.0) 4/3 (1.3)
Down syndrome (%)2 2 (0.3%) 2 (0.3) 0 0 0 0
Median age in years (range) 3.85 (0.95-15.0) 3.78 (0.95-15.0) 6.58 (5.23-7.45) 11.6 (5.37-14.2) 3.85 (3.72-4.01) 4.68 (2.86-13.2)
Median WBC x 109/L (range) 6.5 (0.4-291) 6.5 (0.4-291) 2.4 (2.1-7.0) 62.8 (2.0-106) 10.6 (4.1-30.7) 4.0 (1.5-10)
Extramedullary leukemia (%)2
Central nervous system 13/706 (1.8) 11/686 (1.6) 0/4 1/6 (17) 1/3 (33) 0/7
Mediastinal mass 9/706 (1.3) 9/686 (1.3) 0/4 0/6 0/3 0/7
Testes3 3/354 (0.8) 3/342 (0.9) 0/3 0/3 0/2 0/4
1In cases with 51-67 chromosomes; 2data missing for some variables in the HeH cases: Down syndrome (n=8), central nervous system involvement (n=7), mediastinal mass (n=7),
and testicular involvement (n=5); 3percentage of males. HeH: high hyperdiploidy without t(1;19)(q21;q23), t(9;22)(q34;q11), der(11q23), or t(12;21)(p13;q22); WBC: white blood
cell count.
of the gains correlated with pOS (Online Supplementary
Table S4). Cases positive for triple trisomies (P=0.003) or
with modal numbers >53/55 (P=0.020/0.031) had higher
pEFS; there was no significant difference in pOS. Neither
pEFS nor pOS varied significantly with the presence of
structural changes as such, 1q gain, 6q deletion, or 17q
gain.
Multivariate analysis of clinical and cytogenetic 
features in relation to survival among the high 
hyperdiploid patients
A total of 344 HeH patients treated according to the
NOPHO ALL 1992/2000 protocols were completely
informative for age, WBC count, triple trisomies, and
modal number. Compared with the HeH cases lacking
data on modal chromosome number and/or triple tri-
somies, this subgroup of 344 patients did not differ signif-
icantly as regards pOS (P=0.335) whereas pEFS was some-
what increased (P=0.041). 
A multivariate analysis of age, WBC count, and modal
numbers as continuous variables revealed that all these
three parameters were significantly associated with pEFS,
with high modal numbers (P=0.003; Figure 3), low WBC
counts (P=0.009), and young age (P=0.027) being associat-
ed with favorable outcome, whereas a multivariate analy-
sis of age, WBC count, and triple trisomies showed that
low WBC counts (P=0.011) and presence of triple tri-
somies (P=0.004; Figure 4) were associated with superior
pEFS; in this analysis, young age was not significant
(P=0.09). When including both modal numbers and triple
trisomies, only low WBC counts were significantly associ-
ated with superior pEFS (P=0.009); the three other param-
eters were not significant – young age (P=0.052), high
modal numbers (P=0.056), and presence of triple trisomies
(P=0.081). 
As regards pOS, a multivariate analysis of age, WBC
count, and modal numbers as continuous variables
revealed that only young age was significantly associated
with superior survival (P=0.021), whereas low WBC
counts and high modal numbers were not (P=0.069 and
P=0.1, respectively). The same was true when including
triple trisomies instead of modal number (young age:
P=0.045; low WBC counts: P=0.084; presence of triple tri-
somies: P=0.1) and when including both modal numbers
and triple trisomies (young age: P=0.034; low WBC
counts: P=0.079; presence of triple trisomies: P=0.33; high
modal number: P=0.30).
Discussion
The present population-based, consecutive, and uni-
formly treated series of HeH childhood ALL, comprising
30% of all B-cell precursor ALL cases diagnosed in the
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Table 2. Risk classification, response, and primary events in the 708 children with high hyperdiploid B-cell precursor ALL treated according to the
NOPHO ALL 1992/2000 protocols.
Total HeH t(1;19)1 t(9;22)1 der(11q23)1 t(12;21)1
(n = 708; 100%) (n = 688; 97.2%) (n = 4; 0.6%) (n = 6; 0.8%) (n = 3; 0.4%) (n = 7; 1.0%)
Treatment protocol (%)
ALL 1992 389 (55) 378 (55) 2 (50) 6 (100) 2 (67) 1 (14)
ALL 2000 319 (45) 310 (45) 2 (50) 03 1 (33) 6 (86)
Classification (%)
Standard risk 344 (49) 336 (49) 3 (75) 0 1 (33) 4 (57)
Intermediate risk 260 (37) 259 (38) 0 0 0 1 (14)
High risk 104 (15) 93 (14) 1 (25) 6 (100) 2 (67) 2 (29)
BM blasts day 15/day 29 (%)2
<5% 444 (77)/628 (96) 434 (77)/609 (96) 2 (100)/4 (100) 3 (75)/6 (100) 2 (100)/3 (100) 3 (50)/6 (86)
5-25% 102 (18)/23 (3.5) 101 (18)/22 (3.5) 0/0 0/0 0/0 1 (17)/1 (14)
>25% 30 (5.2)/3 (0.5) 27 (4.8)/3 (0.5) 0/0 1 (25)/0 0/0 2 (33)/0
Complete remission (%)2 688 (98.7) 669 (98.7) 3 (100) 6 (100) 3 (100) 7 (100)
Primary events (%)
Fist complete remission 572 (81) 555 (81) 4 (100) 4 (67) 2 (67) 7 (100)
Induction failure/resistant disease 8 (1.1) 8 (1.2) 0 0 0 0
Relapse 100 (14) 99 (14) 0 1 (17) 0 0
BM 72 (72) 71 (72) 0 1 (100) 0 0
CNS 11 (11) 11 (11) 0 0 0 0
Testes 1 (1.0) 1 (1.0) 0 0 0 0
BM and CNS 8 (8.0) 8 (8.1) 0 0 0 0
BM and testes 3 (3.0) 3 (3.0) 0 0 0 0
BM, CNS, and testes 1 (1.0) 1 (1.0) 0 0 0 0
BM and other site 4 (4.0) 4 (4.0) 0 0 0 0
Dead in first complete remission 17 (2.4) 16 (2.3) 0 0 1 (33) 0
Second malignant neoplasm 11 (1.6) 10 (1.5) 0 1 (17) 0 0
Acute myeloid leukemia 3 (27) 3 (30) 0 0 0 0
Myelodysplastic syndrome 6 (55) 6 (60) 0 0 0 0
Other 2 (18) 1 (10) 0 1 (100) 0 0
1In cases with 51-67 chromosomes; 2data missing for some variables: BM blasts on day 15 (n=134), BM blasts on day 29 (n=55), and achievement of complete remission (n=12);
3cases with t(9;22) were not included in the NOPHO ALL 2000 protocol. BM: bone marrow; CNS: central nervous system; HeH: high hyperdiploidy without t(1;19)(q21;q23),
t(9;22)(q34;q11), der(11q23), or t(12;21)(p13;q22); 
Nordic countries between 1992 and 2008, is one of the
largest reported to date. The patients were characterized
by young age, low WBC counts, rare occurrence of
extramedullary leukemia, and an equal sex ratio, all in line
with findings in previously published series.1 Furthermore,
the distribution of the modal number (Online
Supplementary Figure S1A) and the frequencies of specific
numerical (Online Supplementary Figure S2) and structural
chromosome aberrations also agree well with other stud-
ies.1,2,4,5 Thus, this cohort of patients is clearly representa-
tive of the HeH subgroup. 
Among the 713 HeH cases, 20 (2.8%) harbored the well-
known ALL-associated translocations/fusion genes
t(1;19)/TCF3-PBX1, t(9;22)/BCR-ABL1, t(12;21)/ETV6-
RUNX1, or der(11q23)/MLL rearrangements (Online
Supplementary Table S1), a frequency on a par with the pre-
viously reported 1-4% t-HeH in pediatric HeH ALL.5,17
Such cases are usually risk-grouped to the respective
translocation-positive subgroup,5 and they were, there-
fore, excluded from the main analyses of clinical and sur-
vival data in the present study. However, little is known
about the prognostic implications of these rearrangements
in an HeH context. We found no significant differences
between the HeH and t-HeH groups regarding WBC
counts, incidence of extramedullary leukemia, achieve-
ment of complete remission, pEFS, or pOS (Tables 1 and 2;
Online Supplementary Table S3). On the other hand, the t-
HeH patients were significantly older (Table 1). Since
increased age is an established risk factor in childhood
ALL,18 this could indicate that the limited number of t-HeH
cases in the present investigation precluded detection of
differences in survival compared with HeH cases.
However, it has been reported that t(1;19)-positive t-HeH
cases are associated with favorable presenting characteris-
tics, such as young age, low WBC counts, and lack of
extramedullary leukemia, and a low incidence of
K. Paulsson et al.
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Figure 1. Event-free
(A) and overall survival
(B) of 688 HeH cases
by gender.
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Figure 2. Event-free (A)
and overall survival (B)
of 688 HeH cases by
white blood cell count
(WBC).
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relapse,2,19 like the t(1;19)-positive cases in the present
series (Tables 1 and 2; Online Supplementary Table S3). As
far as concerns t-HeH patients with t(9;22), it has been
suggested that they either have a more favorable survival
and/or treatment response compared with t(9;22)-positive
near-diploid ALL20,21 or the same dismal outcome as all
other patients with this translocation.22,23 The fact that all
six t-HeH with t(9;22) in our Nordic cohort achieved com-
plete remission and all but one remain alive would rather
agree with the former view (Table 2; Online Supplementary
Table S1). Obviously, larger series are needed to address
this clinically important issue, and this is something that
will require international collaboration due to the rarity of
t-HeH in pediatric patients.
In childhood ALL in general, several clinical features
have been associated with outcome.18 In the present HeH
cohort, gender only had an impact on pEFS, whereas WBC
counts, risk group, and percentage of bone marrow blasts
at days 15 and 29 were significant factors for both pEFS
and pOS (Table 3). Since the WBC count is an important
parameter for risk stratification in the NOPHO ALL proto-
cols,14 it is not surprising that the risk group assignments
correlated with survival considering the strong impact of
high WBC counts on pEFS and pOS. That boys with HeH
have a lower pEFS is in line with what was found in a pre-
vious study of a HeH series of similar size from the UK
(Figure 1).5 However, in contrast to the UK series, we also
detected significantly lower pOS in cases with high WBC
counts (Figure 2). These differences between the UK and
the Nordic countries may well be spurious, but could also
reflect different treatment regimens. 
Another factor that has been associated with an unfa-
vorable outcome in pediatric ALL is DS.24,25 In the present
study, only two (0.3%) of the patients had DS, correspon-
ding to 2.6% of all DS-ALL diagnosed during this time
period (data not shown). The former frequency is similar to
the one described by Heerema et al.,4 whereas the latter is
lower than the 5-16% previously reported in DS-ALL.26-30
Both DS patients in our series are alive in first complete
remission more than 9 years after diagnosis. Thus, our
data neither support a notable prevalence of DS in HeH
patients nor indicate a particularly poor outcome of DS-
HeH cases. However, the prognosis of DS-HeH patients
must be ascertained in much larger series. 
In the present study, some cytogenetic aberrations were
found to be significantly associated with certain clinical
features at diagnosis. For example, +4 and +6 were more
common in girls than in boys. We know of no prior study
reporting such gender-related cytogenetic differences in
HeH, and when reviewing all published HeH kary-
otypes,17 no skewed sex ratios were detected (data not
shown). Thus, the observed gender variations may well be
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Table 3. Survival in relation to clinical features of the 688 HeH patients treated according the ALL 1992/2000 protocols.
Variable1 N. of cases (%) pEFS at 5 years (SE) pEFS at 10 years (SE) P2 pOS at 5 years (SE) pOS at 10 years (SE) P2
Gender
Female 342 (50) 0.86 (0.02) 0.84 (0.02) 0.006 0.94 (0.01) 0.92 (0.02) 0.061
Male 346 (50) 0.79 (0.02) 0.76 (0.02) 0.89 (0.02) 0.87 (0.02)
Age
1-4 years 477 (69) 0.85 (0.02) 0.82 (0.02) 0.117 0.92 (0.01) 0.90 (0.01) 0.120
5-9 years 148 (22) 0.76 (0.04) 0.74 (0.04) 0.91 (0.02) 0.90 (0.03)
10+ years 63 (9.2) 0.79 (0.05) 0.79 (0.05) 0.88 (0.04) 0.82 (0.05)
WBC count
<50x109/L 639 (93) 0.83 (0.02) 0.81 (0.02) 0.017 0.92 (0.01) 0.90 (0.01) 0.009
≥50x109/L 49 (7.1) 0.71 (0.07) 0.71 (0.07) 0.78 (0.06) 0.78 (0.06)
CNS disease
Yes 11 (1.6) 0.73 (0.13) 0.73 (0.13) 0.420 0.91 (0.09) 0.91 (0.09) 0.990
No 670 (98) 0.82 (0.02) 0.80 (0.02) 0.91 (0.01) 0.89 (0.01)
Mediastinal mass
Yes 9 (1.3) 0.67 (0.16) 0.67 (0.16) 0.190 0.78 (0.14) 0.78 (0.14) 0.205
No 672 (99) 0.83 (0.02) 0.80 (0.02) 0.92 (0.01) 0.90 (0.01)
Risk group
SR 336 (49) 0.84 (0.02) 0.81 (0.02) <0.001 0.93 (0.02) 0.90 (0.02) 0.003
IR 259 (38) 0.85 (0.02) 0.84 (0.02) 0.93 (0.02) 0.92 (0.02)
HR 93 (14) 0.67 (0.05) 0.67 (0.05) 0.80 (0.04) 0.80 (0.04)
BM blasts day 15
<5% 434 (77) 0.87 (0.02) 0.85 (0.02) <0.001 0.93 (0.01) 0.93 (0.01) <0.001
5-25% 101 (18) 0.73 (0.05) 0.72 (0.05) 0.91 (0.03) 0.87 (0.04)
>25% 27 (4.8) 0.59 (0.10) 0.51 (0.11) 0.77 (0.09) 0.69 (0.11)
BM blasts day 29
<5% 609 (96) 0.84 (0.02) 0.82 (0.02) 0.001 0.93 (0.01) 0.91 (0.01) 0.002
5-25% 22 (3.5) 0.59 (0.11) 0.59 (0.11) 0.76 (0.09) 0.71 (0.10)
>25% 3 (0.5) 0.67 (0.27) nd 0.67 (0.27) nd
1Data missing for some variables: CNS disease (n = 7), mediastinal mass (n = 7), BM blasts at day  15 (n = 126), and BM blasts at day 29 (n = 54); 2significant P values are in bold
type. ALL: acute lymphoblastic leukemia; BM: bone marrow; CNS: central nervous system; HeH: high hyperdiploidy without t(1;19)(q21;q23), t(9;22)(q34;q11), der(11q23), or
t(12;21)(p13;q22); HR: high risk; IR: intermediate risk; nd: not determined; pEFS: probability of event-free survival; pOS: probability of overall survival; SE: standard error; SR: standard
risk; WBC: white blood cells.
fortuitous. The WBC counts were lower for cases with +4
than for cases disomic for this chromosome. Again, since
no previous studies have reported such an association, this
finding should be interpreted with caution. However, low
WBC counts in HeH with gain of chromosome 4 would
agree well with the significantly higher pEFS in such cases
(Online Supplementary Table S4). As regards structural
changes as such, they did not vary in relation to WBC
counts or gender, nor did 1q gain, 6q deletion, or 17q gain.
On the other hand, patients with HeH and structural
changes were significantly older than those with only
numerical changes. Interestingly, this is also the case when
reviewing published HeH cases,17 in which the median
ages were 4 years for HeH patients with structural
changes and 3 years for cases without. This would also be
in line with a recent single nucleotide polymorphism array
study of HeH showing that cases with 17q gain were older
than those without such changes.31 We also observed sig-
nificant differences in age distributions for patients with +
6, +17, and +18, with these trisomies being more common
in younger children. In published HeH cases,17 the median
ages of trisomy-positive and disomy-positive cases for
these three chromosomes are 3 and 4 years, respectively.
Thus, trisomies 6, 17, and 18 are clearly typical for young
age HeH. The biological implications of the observed age-
related cytogenetic differences are, however, unknown.
Certain cytogenetic features were – in univariate analy-
ses – also significantly associated with higher pEFS, name-
ly + 4, +6, +17, +18, and +22, presence of triple trisomies,
and high modal numbers, whereas structural changes as
such, 1q gain, 6q deletion, and 17q gain were not associat-
ed with pEFS. However, no karyotypic patterns correlated
with pOS (Online Supplementary Table S4). As regards the
impact of certain gains on pEFS, our results agree, at least
to some extent, with those of previous studies from the
USA and the UK in which significantly higher pEFS were
also observed among HeH patients with gains of chromo-
somes 4, 17, and 18; however, in contrast to our study,
these gains also correlated with higher pOS in the UK
series.4,5,32 The triple trisomies +4, +10, and +17 were also
associated with a favorable pEFS in this Nordic series, in
line with COG data.12 However, in agreement with UK tri-
als,7 the concurrent presence of these gains did not trans-
late into superior OS (Figure 4). The finding of a better
outcome, at least as regards pEFS, of HeH cases with high-
er modal chromosome numbers (Figure 3), with pEFS gen-
erally increasing with increasing modes (Online
Supplementary Table S2), was not unexpected considering
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Figure 3. Event-free (A)
and overall survival (B)
of HeH cases by modal
chromosome number.
The pEFS and pOS
analyses are based on
the 344 patients
informative for all the
following parameters:
age, WBC count, triple
trisomies, and modal
number. 
Figure 4. Event-free (A)
and overall survival (B)
of HeH cases by pres-
ence/absence of triple
trisomies (+4, +10,
+17). The pEFS and
pOS analyses are
based on the 344
patients informative
for all the following
parameters: age, WBC
count, triple trisomies,
and modal number.
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several prior studies describing such an association.2,4,5
Why high modal numbers would be a favorable prognos-
tic factor is, however, enigmatic. One may speculate that
lymphoblasts with high chromosome content are more
susceptible to chemotherapy,33 but this hypothesis awaits
investigation. 
The favorable impact of both triple trisomies and high
modal numbers (Online Supplementary Table S4) suggests a
close relationship between these two parameters. In fact,
there is much support for this proposition. First, in our
series, the modal chromosome numbers were significantly
higher in triple trisomy-positive cases than in negative
cases (Online Supplementary Figure S1B and C). Second, one
could argue that the more chromosomes, the more triple
trisomies, considering the quite restricted number of dif-
ferent frequent chromosome gains in HeH.1,34 In fact, in the
large series of HeH cases reviewed by Heerema et al.,35 the
frequencies of individual gains of chromosomes 4, 10, and
17 increased from 13-29% at mode 51 to 67-100% at
mode 67. Thus, by necessity, triple trisomies must be
more common at higher modes. Third, in the present mul-
tivariate analyses, low WBC count, young age, and high
modal number were all associated with superior pEFS; the
same was true for low WBC count, young age, and pres-
ence of triple trisomies. However, when including both
modal number and triple trisomies, only WBC count
remained statistically significant. The multicollinearity
between high modal chromosome numbers and the pres-
ence of triple trisomies clearly proves that they are highly
correlated. We, therefore, conclude that these two cytoge-
netic features identify the same subgroup of patients – an
HeH cohort with a favorable prognosis. This begs the
question: “which came first: the chicken or the egg?”,
triple trisomies or high modal numbers? Considering that
there is ample evidence, based on a 2:2 allelic ratio of loci
on tetrasomic chromosomes and few uniparental isodis-
omies in HeH cases, that the high hyperdiploid pattern
usually arises as a simultaneous gain of chromosomes in
one abnormal mitosis,36-38 it seems most likely that the
modal number is established first, with cases with high
modal numbers also harboring several trisomies, including
+4, +10, and +17. Thus, the triple trisomies are surrogate
markers for high modal chromosome numbers and do not
by themselves have a favorable prognostic impact. 
In conclusion, in this population-based, consecutive
Nordic series of 688 uniformly treated HeH cases, the
most important factor for superior pEFS was low WBC
count, with young age and high modal numbers/triple tri-
somies also being significantly associated with favorable
outcome.
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